# A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of ASP2215

> **NCT02571816** · PHASE1 · COMPLETED · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 24 (actual)

## Conditions studied

- Hepatic Impairment
- Healthy

## Interventions

- **DRUG:** ASP2215

## Key facts

- **NCT ID:** NCT02571816
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-23
- **Primary completion:** 2016-03-05
- **Final completion:** 2016-03-05
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2024-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02571816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02571816, "A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of ASP2215". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT02571816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*